Get the Stockscreener App
0.6436
4.28%
-0.0287
After Hours:
.64
-0.00363
-0.56%
Novabay Pharmaceuticals Inc stock is traded at $0.6436, with a volume of 27,368.
It is down -4.28% in the last 24 hours and up +6.24% over the past month.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
See More
Previous Close:
$0.6724
Open:
$0.66
24h Volume:
27,368
Relative Volume:
0.73
Market Cap:
$3.74M
Revenue:
$14.64M
Net Income/Loss:
$-13.74M
P/E Ratio:
-0.0885
EPS:
-7.27
Net Cash Flow:
$-5.04M
1W Performance:
-1.36%
1M Performance:
+6.24%
6M Performance:
-5.90%
1Y Performance:
-8.08%
1-Day Range:
$0.6436
$0.6742
1-Week Range:
$0.6311
$0.6899
52-Week Range:
$0.3611
$1.0099
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Name
Novabay Pharmaceuticals Inc
Sector
Industry
Phone
510-899-8800
Address
2000 Powell Street, Suite 1150, Emeryville, CA
Compare NBY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.6436 | 3.91M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-19 | Initiated | Ladenburg Thalmann | Buy |
| Jul-06-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Reiterated | Laidlaw | Buy |
| Jun-05-17 | Initiated | ROTH Capital | Buy |
| Mar-27-17 | Initiated | Laidlaw | Buy |
| Feb-06-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-14-15 | Reiterated | Maxim Group | Buy |
| Apr-30-15 | Resumed | Maxim Group | Buy |
| Mar-06-13 | Initiated | Ascendiant Capital Markets | Strong Buy |
| Jan-03-08 | Initiated | Dawson James | Speculative Buy |
View All
Novabay Pharmaceuticals Inc Stock (NBY) Latest News
What makes NovaBay Pharmaceuticals Inc. stock price move sharplyBreakthrough stock performance - jammulinksnews.com
Market reaction to NovaBay Pharmaceuticals Inc.’s recent newsHigh Accuracy Trade Setup Identification - Newser
Using data tools to time your NovaBay Pharmaceuticals Inc. exitExpert-Backed High Yield Stock Watchlist - Newser
When is NovaBay Pharmaceuticals Inc. stock expected to show significant growthEarnings Report Ideas With High Returns - jammulinksnews.com
Why NovaBay Pharmaceuticals Inc. stock attracts strong analyst attention Pattern Recognition Based Market Move Prediction - Newser
Short interest data insights for NovaBay Pharmaceuticals Inc. Free Short Term Buy Zone Stock Alerts - Newser
How Resilient Is NovaBay Pharmaceuticals Inc. Stock During Economic DownturnsFree Smart Money Stock Analysis - metal.it
Is NovaBay Pharmaceuticals Inc. stock overvalued or undervaluedGet timely alerts on top market movers - jammulinksnews.com
What institutional investors are buying NovaBay Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - jammulinksnews.com
Should I hold or sell NovaBay Pharmaceuticals Inc. stock in 2025Capitalize on emerging industry trends - jammulinksnews.com
How does NovaBay Pharmaceuticals Inc. compare to its industry peersBreakthrough profit margins - jammulinksnews.com
Buy Signal for NovaBay Pharmaceuticals Inc. Stock Key Technical Indicators to WatchHigh Probability Setups - Newser
When is the best time to buy NovaBay Pharmaceuticals Inc. stockDaily Volume Leaders - Newser
Is NovaBay Pharmaceuticals Inc. a good long term investmentUnmatched market gains - PrintWeekIndia
How NovaBay Pharmaceuticals Inc. stock reacts to Fed policy changesMarket-leading growth rates - jammulinksnews.com
What analysts say about NovaBay Pharmaceuticals Inc. stockFree Market Dynamics Reports - PrintWeekIndia
NovaBay Pharmaceuticals Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
What drives NovaBay Pharmaceuticals Inc. stock priceFree Investment Risk Control - Autocar Professional
Why NovaBay Pharmaceuticals Inc. stock attracts strong analyst attentionMinimized Risk Maximum Return - Newser
How NovaBay Pharmaceuticals Inc. stock performs during market volatilityReturn Optimized Trade Insights - Newser
Novabay Pharmaceuticals Inc Stock (NBY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):